Durham funding news: Data and analytics and biotechnology top recent local investments – Yahoo News

Photo: Unsplash

Durham-based therapeutics and product research company Lindy Biosciences has secured $1.6 million in Series A funding, according to company database Crunchbase, topping the citys recent funding headlines. The cash infusion was announced Sept. 18 and led by alumshares.

According to its Crunchbase profile, "Lindy is developing high-dose suspension of protein suitable for subcutaneous injection, which will decrease administration costs, increase patient costs, increase patient comfort and compliance, and enable high-dose molecules to reach the market."

The three-year-old startup has raised two previous funding rounds, including a $547,736 seed round earlier this year.

Over the past year, four Durham-based data and analytics companies have secured venture funding, totaling $32 million in new investment to the local industry.

In other local funding news, pharmaceutical company Emergo Therapeutics announced a $500,000 debt financing funding round on Oct. 15, financed by North Carolina Biotechnology Center.

According to Crunchbase, "Emergo is developing treatment options for flu-like illnesses and to boost the bodys immune system response."

The company also raised a $12 million Series A round in 2018.

This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.

Read the original here:
Durham funding news: Data and analytics and biotechnology top recent local investments - Yahoo News

VBI Vaccines Inc. (VBIV) vs. TIM Participacoes S.A. (TSU): Comparing the Biotechnology Industrys Most Active Stocks – E Globalist

VBI Vaccines Inc. (NASDAQ:VBIV) shares are down more than -65.31% this year and recently increased 0.84% or $0.01 to settle at $0.56. TIM Participacoes S.A. (NYSE:TSU), on the other hand, is up 4.29% year to date as of 11/08/2019. It currently trades at $15.38 and has returned 7.70% during the past week.

VBI Vaccines Inc. (NASDAQ:VBIV) and TIM Participacoes S.A. (NYSE:TSU) are the two most active stocks in the Biotechnology industry based on todays trading volumes. We will compare the two companies based on the strength of various metrics, including growth, profitability, risk, return, and valuation to determine if one is a better investment than the other.

One of the key things investors look for in a company is the ability to grow earnings at a high compound rate over time. Comparatively, TSU is expected to grow at a 5.90% annual rate. All else equal, TSUs higher growth rate would imply a greater potential for capital appreciation.

Growth isnt very attractive to investors if companies are sacrificing profitability and shareholder returns to achieve that growth. We will use EBITDA margin and Return on Investment (ROI), which control for differences in capital structure between the two companies, to measure profitability and return. EBITDA margin of 11.13% for TIM Participacoes S.A. (TSU).

Cash is king when it comes to investing. VBIVs free cash flow (FCF) per share for the trailing twelve months was -0.14. Comparatively, TSUs free cash flow per share was +0.46. On a percent-of-sales basis, VBIVs free cash flow was -0.74% while TSU converted 4.79% of its revenues into cash flow. This means that, for a given level of sales, TSU is able to generate more free cash flow for investors.

VBIV trades at a P/B of 0.71, and a P/S of 25.09, compared to a forward P/E of 17.58, a P/B of 1.40, and a P/S of 1.76 for TSU. Given that earnings are what matter most to investors, analysts tend to place a greater weight on the P/E.

Analyst Price Targets and Opinions

When investing its crucial to distinguish between price and value. As Warren Buffet said, price is what you pay, value is what you get. VBIV is currently priced at a -93.21% to its one-year price target of 8.25. Comparatively, TSU is -13.89% relative to its price target of 17.86. This suggests that VBIV is the better investment over the next year.

Insider Activity and Investor Sentiment

Comparing the number of shares sold short to the float is a method analysts often use to get a reading on investor sentiment. VBIV has a short ratio of 2.09 compared to a short interest of 4.29 for TSU. This implies that the market is currently less bearish on the outlook for VBIV.

TIM Participacoes S.A. (NYSE:TSU) beats VBI Vaccines Inc. (NASDAQ:VBIV) on a total of 7 of the 14 factors compared between the two stocks. TSU has lower financial risk, is more profitable, generates a higher return on investment, has higher cash flow per share, has a higher cash conversion rate and higher liquidity.

See the original post:
VBI Vaccines Inc. (VBIV) vs. TIM Participacoes S.A. (TSU): Comparing the Biotechnology Industrys Most Active Stocks - E Globalist

PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely – Yahoo Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.

So should PDS Biotechnology (NASDAQ:PDSB) shareholders be worried about its cash burn? For the purpose of this article, we'll define cash burn as the amount of cash the company is spending each year to fund its growth (also called its negative free cash flow). The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.

View our latest analysis for PDS Biotechnology

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. As at September 2019, PDS Biotechnology had cash of US$17m and such minimal debt that we can ignore it for the purposes of this analysis. Looking at the last year, the company burnt through US$12m. So it had a cash runway of approximately 17 months from September 2019. That's not too bad, but it's fair to say the end of the cash runway is in sight, unless cash burn reduces drastically. The image below shows how its cash balance has been changing over the last few years.

NasdaqCM:PDSB Historical Debt, November 12th 2019

Because PDS Biotechnology isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Remarkably, it actually increased its cash burn by 673% in the last year. With that kind of spending growth its cash runway will shorten quickly, as it simultaneously uses its cash while increasing the burn rate. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

While PDS Biotechnology does have a solid cash runway, its cash burn trajectory may have some shareholders thinking ahead to when the company may need to raise more cash. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Commonly, a business will sell new shares in itself to raise cash to drive growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

PDS Biotechnology has a market capitalisation of US$15m and burnt through US$12m last year, which is 85% of the company's market value. That suggests the company may have some funding difficulties, and we'd be very wary of the stock.

Even though its cash burn relative to its market cap makes us a little nervous, we are compelled to mention that we thought PDS Biotechnology's cash runway was relatively promising. Considering all the measures mentioned in this report, we reckon that its cash burn is fairly risky, and if we held shares we'd be watching like a hawk for any deterioration. For us, it's always important to consider risks around cash burn rates. But investors should look at a whole range of factors when researching a new stock. For example, it could be interesting to see how much the PDS Biotechnology CEO receives in total remuneration.

Story continues

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies, and this list of stocks growth stocks (according to analyst forecasts)

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Read the rest here:
PDS Biotechnology (NASDAQ:PDSB) Will Have To Spend Its Cash Wisely - Yahoo Finance

Vir Biotechnology

Vir is a science-driven company guided by medical need.

Vir integrates diverse innovations in science, technology, and medicine to transform the care of people with serious infectious diseases. Vir is taking a multi-program, multi-platform approach to applying these breakthroughs, including the development of treatments that induce protective and therapeutic immune responses. Virs scale and scope, together with leading scientific and management expertise, allow it to perform significant internal R&D, in-license or acquire innovative technology platforms and assets, and fund targeted academicresearch.

Virs initial focus is in three areas of significant unmet need: chronic infectious diseases including hepatitis B, tuberculosis, and HIV; respiratory diseases, including influenza, respiratory syncytial virus (RSV), and metapneumovirus (MPV); and health-care acquiredinfections.

The company was founded by Robert Nelsen and ARCH Venture Partners and seeded by ARCH, the Bill & Melinda Gates Foundation, Altitude Life Sciences, and Alta Partners. Additional investors include the SoftBank Vision Fund, Temasek, Baillie Gifford, the Alaska Permanent Fund, and select sovereign wealth funds, private individuals, family offices, and other institutionalinvestors.

Vir is headquartered in San Francisco, California with operations in Portland, Oregon, Boston, Massachusetts, and Bellinzona,Switzerland

More:
Vir Biotechnology

Powershares Dynamic Biotechnology and Genome Portfolio (PBE) TEMA Trending Higher – FLBC News

Powershares Dynamic Biotechnology and Genome Portfolio (PBE)sTriple Exponential Moving Average has been spotted as trending higher over the past five bars, suggesting that momentum is building for the shares. Triple Exponential Moving Average (also referred to as TEMA) was developed by Patrick Mulloy and was first published in the Technical Analysis of Stocks & Commodities magazine. The main purpose in developing of this indicator was reducing the lag between the indicator and price action by making it fast-acting and more sensitive to market changes. In similar to other moving averages way, the TEMA indicator is used to identify trends and generate trading signals.

The Relative Strength Index (RSI) is another highly popular momentum indicator used for technical analysis. The RSI can help display whether the bulls or the bears are currently strongest in the market. The RSI may be used to help spot points of reversals more accurately. The RSI was developed by J. Welles Wilder. As a general rule, an RSI reading over 70 would signal overbought conditions. A reading under 30 would indicate oversold conditions. As always, the values may need to be adjusted based on the specific stock and market. RSI can also be a valuable tool for trying to spot larger market turns. Powershares Dynamic Biotechnology and Genome Portfolio (PBE) has a 14-day RSI of 63.49, the 7-day is at 73.49, and the 3-day is resting at 85.06.

Powershares Dynamic Biotechnology and Genome Portfolio (PBE) currently has a 14-day Commodity Channel Index (CCI) of 180.47. Active investors may choose to use this technical indicator as a stock evaluation tool. Used as a coincident indicator, the CCI reading above +100 would reflect strong price action which may signal an uptrend. On the flip side, a reading below -100 may signal a downtrend reflecting weak price action. Using the CCI as a leading indicator, technical analysts may use a +100 reading as an overbought signal and a -100 reading as an oversold indicator, suggesting a trend reversal.

Shares of Powershares Dynamic Biotechnology and Genome Portfolio (PBE) have a 200-day moving average of 43.16. The 50-day is 46.48, and the 7-day is sitting at 46.82. Using a bigger time frame to assess the moving average such as the 200-day, may help block out the noise and chaos that is often caused by daily price fluctuations. In some cases, MAs may be used as strong reference points for spotting support and resistance levels.

The Average Directional Index or ADX is technical analysis indicator used to describe if a market is trending or not trending. The ADX alone measures trend strength but not direction. Using the ADX with the Plus Directional Indicator (+DI) and Minus Directional Indicator (-DI) may help determine the direction of the trend as well as the overall momentum. Many traders will use the ADX alongside other indicators in order to help spot proper trading entry/exit points. Currently, the 14-day ADX for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is 15.56. Generally speaking, an ADX value from 0-25 would indicate an absent or weak trend. A value of 25-50 would indicate a strong trend. A value of 50-75 would signal a very strong trend, and a value of 75-100 would indicate an extremely strong trend. The Williams Percent Range or Williams %R is another technical indicator that may be useful for traders and investors.

The Williams %R is designed to provide a general sense of when the equity might have reached an extreme and be primed for a reversal. As a general observance, the more overbought or oversold the reading displays, the more likely a reversal may take place. The 14 day Williams %R for Powershares Dynamic Biotechnology and Genome Portfolio (PBE) is noted at -1.01. Many consider the equity oversold if the reading is below -80 and overbought if the indicator is between 0 and -20.

Read more here:
Powershares Dynamic Biotechnology and Genome Portfolio (PBE) TEMA Trending Higher - FLBC News

CAR-T: Novartis prices CTL019 at US$475000 – European Biotechnology

Swiss Novartis AG has received US market authorisation for its first-in-class CAR-T cell therapy Kymriah (tisagenlecleucel-T). As severe cytokine storms seemed to be generally linked to CAR-T therapies such as Kymriah, the FDA also authorised Roches anti-IL-6R antibody Actemra (tocilizumab) as first-in-class treatment to manage them.

Novartis, which received unanimous backing from the FDA ODAC committee for its CAR-T cell therapy in Julyto treat young patients with acute lymphoblastic leukemia (ALL), priced Kymriah at US$475,000 per patient, making it one of the most expensive treatments in the world. The pharma major also agreed with the CMS (US Centers for Medicare & Medicaid Services) that patients who do not respond to its therapy wont be charged. Kymriah consists of autologous T cells which were engineered ex vivoto target the CD19 antigen on B lymphocytes. As the CD19 antibody is linked to a immunostimulatory CD3zeta/CD137 signalling domain, T cells kill B lymphocytes upon binding.

The Novartis CAR-T approval is a significant progress for patients and patient communities of the diseases that late-stage clinical CAR-T therapies are targeting, commented the International Society for Cellular Therapy. Besides ALL, Novartis is seeking approval for tisagenlecleucel-T in non-hodgkin lymphoma and diffuse large B cell lymphoma. In September, the FDA will decide over market authorisation of Kite Pharmas CAR-T cell therapy axicabtagene ciloleucel targeting the CD19 antigen on B lymphocytes.Most recently, the company has been subject to a US$11.9bn take-over bid by Gilead Sciences.

FDA approval for Novartis breakthrough therapy was based on the ELIANA trial in which tisagenlecleucel-T showed a remission rate of more than 80% in 63 ALL patients at three months. As up to now, four deaths caused by CAR-T induced cytokine release syndrome (CRS) occured in clinical trails evaluating different CAR-T therapies. Since additional 44% of patients who were enroled in the ELIANA trial showed grade 3 and 4 CRS, the FDA also expanded the label of Roche/Genentechs RA antibodytocilizumab (Actemra) to treat CAR T cell-induced CRS. Actemra helped 69% of patients to resolve CRS 14 days after they received the monoclonal antibody. Until today, there has never been an FDA-approved treatment to manage severe cytokine release syndrome associated with CAR T cell therapy, which is marked by a rapid onset and can cause life-threatening complications, said Sandra Horning, MD, Chief Medical Officer and Head of Global Product Development at Roche. Today's approval of Actemra/RoActemra for CRS provides physicians with an important tool to help manage this potentially life-threatening side effect.

According to the FDA, Kymria must be co-administered with Roches immunosuppressive antibody therapy for management of CRS. However, Actemra could not resolve neurotoxicity of tisagenlecleucel-T treatment, which occured in 44% of patients in the ELIANA trial. As manufacturing of Novartis CAR-T cell therapy is lenghty, complicated and only partly reproducible, the 20-25 medical centre expected by Novaertis set to offer the therapy must receive certification before.

Excerpt from:
CAR-T: Novartis prices CTL019 at US$475000 - European Biotechnology

Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute … – Markets Insider

BOULDER, Colo., Aug. 2, 2017 /PRNewswire/ --Bolder BioTechnology, Inc. announced today that it has commenced dosing of patients in a Phase 1 clinical trial of its proprietary long-acting granulocyte colony-stimulating factor (G-CSF) analog, BBT-015. The trial is designed to study the pharmacokinetics, pharmacodynamics, safety and tolerability of single subcutaneous doses of BBT-015 in healthy human subjects.BBT-015 is being developed as a treatment for chemotherapy-related neutropenia in cancer patients and for Acute Radiation Syndrome.

Joe Cox, Ph.D., Bolder BioTechnology's President said: "Initiation of this clinical trial represents a major milestone for Bolder BioTechnology and the culmination of many years of effort by our dedicated and talented employees."

"BBT-015 is a novel G-CSF analog that exhibits a longer duration of action and greater potency than other G-CSF products. In preclinical studies, BBT-015 stimulated larger and longer-lasting increases in neutrophils, and faster neutrophil recovery in chemotherapy-treated, neutropenic animals compared to other G-CSF products.BBT-015 also significantly increased survival and accelerated recovery of neutrophils, platelets, and red blood cells in animals exposed to lethal doses of radiation, even when administered 24 hours following radiation exposure."

"BBT-015's increased potency and longer duration of action may stimulate faster neutrophil recovery in cancer patients and / or allow the drug to be administered less frequently and at lower doses than competing G-CSF products, with associated cost savings for patients."

"G-CSF products are some of the best selling biopharmaceuticals in the world, with annual worldwide sales exceeding $6 billion, primarily from the treatment of neutropenia in cancer patients."

About BBT-015BBT-015 is a long-acting G-CSF analog produced using site-specific PEGylation technology.G-CSF is a human protein that stimulates production of neutrophils, a type of white blood cell that is important for fighting infections.G-CSF has a short half-life in humans and typically is administered to patients by daily injection.BBT-015 has been selectively modified with the polymer polyethylene glycol at a unique site in the protein, which allows the protein to last longer in patients, reducing the need for frequent administration and increasing the protein's ability to stimulate long-lasting production of neutrophils.

About Chemotherapy-Related NeutropeniaNeutropenia (severely reduced numbers of neutrophils) is a common side effect of chemotherapy treatment in cancer patients.Neutropenia increases the patient's risk of developing serious bacterial infection and requiring expensive hospitalization.G-CSF products are commonly administered to cancer patients following chemotherapy to accelerate neutrophil recovery and decrease the length of time that patients are neutropenic.

About Acute Radiation SyndromeAcute Radiation Syndrome, often referred to as radiation sickness, is a collection of illnesses that occurs following exposure to high doses of ionizing radiation within a short period of time, such as might occur following an accident at a nuclear power plant or detonation of a nuclear weapon.Bone marrow, which is responsible for producing new blood cells, is one of the most radiation-sensitive tissues, and subjects acutely exposed to high doses of radiation typically develop bone marrow aplasia and severe neutropenia and thrombocytopenia (low numbers of platelets) within a few weeks of exposure, Many subjects die from infections due to a lack of neutrophils, or from uncontrolled bleeding due to a lack of platelets.

About Bolder BioTechnologyBolder BioTechnology, Inc. is a private company that uses advanced protein engineering technologies to create proprietary human protein pharmaceuticals with enhanced therapeutic properties for the treatment of hematopoietic and endocrine disorders, cancer and infectious diseases. For additional information about Bolder BioTechnology, Inc., please visit our web site at http://www.bolderbio.com.

Government SupportPreclinical research reported in this press release was supported by The National Cancer Institute and The National Institute of Allergy and Infectious Diseases of the National Institutes of Health under awards R43CA078094, R44CA078094, R43AI084288, R44AI084288, andU01AI107340. The content of this press release is solely the responsibility of Bolder BioTechnology and does not necessarily represent the views of the National Institutes of Health.

Forward Looking StatementsStatements contained herein that are not historical facts are forward-looking statements that are subject to a variety of risks and uncertainties.There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company.These factors include, but are not limited to: (1) the Company's ability to successfully complete product research and development, including pre-clinical and clinical studies, and commercialization; (2) the Company's ability to obtain required government approvals; (3) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (4) the Company's ability to develop and commercialize its products before its competitors.

View original content:http://www.prnewswire.com/news-releases/bolder-biotechnology-announces-initiation-of-phase-1-clinical-trial-of-bbt-015-for-treating-neutropenia-and-acute-radiation-syndrome-300498287.html

SOURCE Bolder BioTechnology, Inc.

More:
Bolder BioTechnology Announces Initiation of Phase 1 Clinical Trial of BBT-015 for Treating Neutropenia and Acute ... - Markets Insider

Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock? July 03, 2017 – Zacks.com

Investors in Puma Biotechnology, Inc. (PBYI - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the July 28th, 2017, $55 Puthad some of the highest implied volatility of all equity options today.

What is Implied Volatility?

Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.

What do the Analysts Think?

Clearly, options traders are pricing in a big move for Puma Biotechnology shares, but what is the fundamental picture for the company? Currently, Puma Biotechnology is a Zacks Rank #3 (Hold) in the Medical-Biomed/Genetics industry that ranks in the Bottom 37% of our Zacks Industry Rank. Over the last 60 days, 2 analysts have increased their earnings estimates for the current quarter, while none have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from loss of $2.33 per shareto a loss of $2.13 in that period.

Given the way analysts feel about Puma Biotechnology right now, this huge implied volatility could mean theres a trade developing. Often times, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.

Looking to Trade Options?

Each week, our very own Dave Bartosiak gives his top options trades. Check out his recent live analysis and options trade for the TSLA earnings report completely free. See it here: Tesla Earnings Preview with Options Trade Ideas or check out the embedded video below for more details:

Follow this link:
Are Options Traders Betting on a Big Move in Puma Biotechnology (PBYI) Stock? July 03, 2017 - Zacks.com

Dr Pushpa Mitra Bhargava, pioneer in biotechnology, passes away at 89 – Times of India

HYDERABAD: Dr P M Bhargava, eminent scientist and founder-director of the city-based Centre for Cellular and Molecular Biology (CCMB), died here on Tuesday after a brief illness. He was 89 and is survived by two children.

Pushpa Mittra Bhargava was born on February 22, 1928. He was a pioneer in the field of biotechnology in India and among the first persons to use the term "genetic engineering". Bhargava was instrumental in the formation of the Department of Biotechnology in the '70s. He was also chairman of Medically Aware and Responsible Citizens of Hyderabad, Sambhavna Trust, Bhopal, and Basic Research, Education and Development Society (BREAD), New Delhi. He served as vice-chairman of the National Knowledge Commission between 2005 and 2007.

Bhargava received over 100 national and international honours and awards. He was awarded the Padma Bhushan in 1986 but returned it in 2015 citing "matters of principle". He was honoured with the Legion d'honneur in 1998. He is popularly known as the architect of modern biology in India.

More here:
Dr Pushpa Mitra Bhargava, pioneer in biotechnology, passes away at 89 - Times of India

Noxxon/MSD start testing of immunoncologic combo – European Biotechnology

Last December, Noxxon Pharma AG signed an agreement with Merck & Co./MSD to evaluate the synergistic potential of NOXA1/2 and pembrolizumab immune cancer therapy. Now, the companies have kicked off a Phase I/II study in patients with pancreatic and colorectal cancer.

The study conducted at the National Center for Tumor Diseases in Heidelberg (Germany) will investigate the impact of NOX-A12 (olaptesed pegol) as a monotherapy on immune cell infiltration into tumors. In addition, Noxxon and Merck & Co will assess safety and efficacy of NOX-A12 in combination with Keytruda (pembrolizumab), Merck & Co./MSDs programmed death receptor-1 (PD-1) immune checkpoint-blocking antibody drug.

The open-label trial (NCT03168139) is composed of two parts: patients will receive NOX-A12 monotherapy for two weeks, followed by combination therapy of NOX-A12 plus pembrolizumab for up to two years. 20 patients will be enroled: 10 patients for each metastatic pancreas and colorectal cancer.

The design of the clinical trial was a collaborative effort between NOXXON and MSD. Part 1 of the study, in which patients will receive NOX-A12 monotherapy for up to two weeks, will evaluate immune infiltrate changes within the tumor microenvironment induced by CXCL12 inhibition with NOX-A12 by comparing pre- and post-treatment biopsy specimens as well as the safety and tolerability of NOX-A12 in patients with metastatic (stage IV) colorectal and pancreatic cancer. Part 2 of the study, in which NOX-A12 is to be combined with Keytruda, will assess the safety and tolerability of the combination in addition to the efficacy of treatment. Top-line data for all 20 patients from part 1 is expected to be available in Q2/2018, and initial response-rate data in Q4/2018.

NOX-A12 inhibits CXCL12, a key tumor microenvironment chemokine and a stem cell migration factor. The chemokine that acts by binding to to CXCR4 and CXCR7 may be a key partner for a wide range of IO (immuno-oncology) agents. Noxxon has generated promising pre-clinical and clinical data, including animal data showing synergy with a checkpoint inhibitor, as well as recent phase 2a trials in multiple myeloma and a second hematological cancer that showed a safety profile that supports further development and first signs of efficacy. The company said that its study will position the drug to be combined with multiple classes of IO approaches including those acting on or through T cells and/or NK cells.

Original post:
Noxxon/MSD start testing of immunoncologic combo - European Biotechnology

Prana Biotechnology shares surge after journal publication – Proactive Investors UK

Shares in Prana Biotechnology (NADSAQ:PRAN) surged 19% and was earlier higher in New York as it said an article about early data on PBT434 had been accepted in a peer review journal.

The article deals with the fact the compound PBT434 prevents iron-mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinsons disease.

Dr David Stamler, Pranas chief medical officer, said: These findings are important because Parkinsons disease and the related synucleinopathies cause significant disability and diminish the independence of afflicted individuals.

"An agent which slows disease progression could have a great impact on reducing disease burden and improving quality of life. We are eager to begin clinical testing of PBT434.

The publication is the culmination of ten years of research from scientists at the Florey Institute of Neuroscience and Mental Health, (Melbourne, Australia), investigating compounds from Prana Biotechnologys propriety chemical library.

Not only was PBT434 shown to block alpha-synuclein accumulation, but it also prevented loss of nerve cells in the region of the brain primarily affected in Parkinsons disease.

To investigate the therapeutic potential of PBT434 to slow neurodegeneration, the researchers performed extensive animal testing in multiple Parkinsons disease models, including tests in mice that over-expressed the alpha-synuclein protein.

These results showed that PBT434 lowered alpha-synuclein and its toxic effects and simultaneously improved motor performance.

Shares added 19% to $2.73.

Read the rest here:
Prana Biotechnology shares surge after journal publication - Proactive Investors UK

At the Crossroads of Art and Biotech, a Warning: Be Careful What You Wish For. – INDY Week

ARTS WORK IN THE AGE OF BIOTECHNOLOGY: SHAPING OUR GENETIC FUTURES

Through Sunday, March 15

The Gregg Museum of Art & Design, Raleigh

Where do we draw the lines dividing art from science, natural from unnatural, and boldness from hubris?

An exhibit at N.C. States Gregg Museum of Art & Design doesnt answer these questions. Instead, it offers head-spinning new ways to ask them at the nexus of art and biotechnology, sharpening our insight into the fields future and expanding our understanding of it into the past.

These hard-to-classify collaborations between artists and scientistsseethe with hot-button issues related to ethics, privacy, human nature, and more. But if they have one message in common, its to be careful what you wish for.

Arts Work in the Age of Biotechnology: Shaping Our Genetic Futures is the result of more than two years of planning led by Molly Renda, the exhibit program librarian at N.C. State University Libraries, and the universitys Genetic Engineering and Society Center. Guest-curated by Hannah Star Rogers, who studies the intersection of art and science, the main exhibit at the Gregg has annexes in Hill and Hunt libraries.

On a recent tour of the exhibit, Renda and Fred Gould, the co-director of the GESC, said that they wanted to bring artists into the welter of science-and-design innovation taking place at the university because their differing perspectives on fundamental human issues create balance, tension, and discovery.

In the course of this, Ive found that artists tend to be more dystopian and designers are more utopian, Renda says.

There are different ways of knowing things, Gould adds. Thats why Molly came up with the name: not artwork, but arts work. What is an artist supposed to do?

Some pieces take on the dangers of day-after-tomorrow DNA testing and engineering technology. Heather Dewey-Hagborg is best known for Probably Chelsea, a piece in which she collected DNA samples from Chelsea Manning and generated thirty-two possible portraits of the soldier and activist.

When we worry about biotechnology, we usually worry that our food is going to be dangerous. But sometimes you wish for something thats rare: What happens when biotechnology makes it available to you?

The Gregg is showing a similar piece in which Dewey-Hagborg harvested DNA from cigarette butts and gum she found on the street and created probablebut not definitereplicas of the litterers faces, which hang on the walls above the specimens. Dewey-Hagborg demonstrates not only the unnerving extent of whats currently possible with DNA testing, but also the limits, which create misidentification risks.

Other pieces probe how biotechnology might reshape life as we know it. In a film and a sculpture representing an ancient Greek rite for women, Charlotte Jarvis raises the possibility of creating female sperm, based on the idea that, because stem cells are undifferentiated, you could theoretically teach womens stem cells to develop into sperm.

Still other pieces pointedly poke holes in the boundary between science and art. Adam Zaretskys Errorarium (entitled "Bipolar Flowers")looks like a cross between an arcade cabinet and a terrarium. It houses a few genetically modified Arabidopsis specimens, which Gould calls the white mice of research plants. When you turn the knobs, it changes the sonic parameters of a synthesizer, notionally testing the effects of the sound on the mutant plants.

It doesnt really do anythingor does it? Zaretskys experiment with no hypothesis is a playful tweak on science with something a little dangerous in the background.

Joe Davis, a bio-art pioneer, touches on something similar in his piece, which consists of documentation of an experiment where mice roll dice to determine if luck can be bred. Renda says that Davis couldnt get permission to run the test (universities are wary of drawing attention for ridiculous-seeming experiments), so he did it as conceptual art at N.C. State, instead.

Its notable that two artists home in on luck, one of many human concepts that genetic engineering, which will allow us to take control of our bodies and environment in untested ways, will transform. In We Make Our Own Luck Here, Ciara Redmond has bred four-leaf clovers (without genetic modification), which ruins themtheyrelucks evidence, not its cause. This whimsical iteration of unconsidered consequences raises a serious question: What else are we not thinking of?

When we worry about biotechnology, we usually worry that our food is going to be dangerous, Gould says. But sometimes you wish for something thats rare: What happens when biotechnology makes it available to you?

The exhibit takes an expansive view of biotechnology. Maria McKinney uses semen-extraction straws to sculpt proteins from double-muscled breeding bulls, underscoring that weve been tampering with life since long before CRISPR. Biotech feels radically new, but its revealed as part of a centuries-long process.

Another part of the exhibit, which closed at the end of October but can still be experienced through virtual reality at the Gregg, was From Teosinte to Tomorrow, Rendas land-art project at the North Carolina Museum of Art. In what was essentially a walk back through agricultural history, a bed of teosinte, which is thought to be the ancestor of modern maize, waited at the center of a corn maze.

That teosinte was in some sense genetically enhanced by subsistence farmers in Mexico since the time of the Aztecs, Gould says. Now were doing it in the laboratory with the same genesso whats the difference? Arts work is to make us think and question.

Contact arts and culture editor Brian Howe at bhowe@indyweek.com

Support independent local journalism.Join the INDY Press Clubto help us keep fearless watchdog reporting and essential arts and culture coverage viable in the Triangle.

Visit link:
At the Crossroads of Art and Biotech, a Warning: Be Careful What You Wish For. - INDY Week

Puma Stalks Up – Puma Biotechnology, Inc. (NYSE:PBYI) | Seeking … – Seeking Alpha

Puma Biotechnology, (NYSE:PBYI) is a $3.2 billion market cap company initially focused on developing tyrosine kinase inhibitor neratinib (PB272) for HER2 positive breast cancer. The company has conducted 11 clinical trials for its lead candidate, with over 2,000 patients contributing to a favorable risk-benefit profile, per inflection point clinical trial readouts over the past quarter. Oncologic Drugs Advisory Committee (ODAC) at FDA recently voted for approval of neratinib in HER2 positive extended adjuvant treatment of early stage breast cancer in May 2017. ODAC vote is not binding but carries strong weight in the decision-making process. Given FDA director Gottlieb's new aggressive policies regarding the slow and outdated drug approval process at FDA, this was seen by the market as a "sure thing". The company is advancing neratinib in discussions with EMA for European markets, with validation in August 2016. Other investigations include neratinib in combinatory therapy for metastatic breast cancer and in solid tumors as well.

Neratinib blocks signal cascades of epidermal growth factor receptors or EGFRs, specifically: HER1, HER2, HER3, and HER4. A number of studies are showing nice anti-tumor efficacy. Taken together with ODAC favor, Phase 3 result emphasis for neratinib which met primary endpoints appears to have led to the robust response in the market for high probability of FDA approval. Two-year disease-free survival showed a 2.4% improvement for neratinib versus placebo in ITT population. Five-year disease-free survival showed a 2.5% improvement. In HR+ patients, neratinib adjuvant therapy showed a two-year disease-free survival rate of 95.4% compared to 91.2% in placebo. Five-year disease-free survival conferred a 4.8% benefit. Two-year HR patients' disease-free survival showed a meaningful advantage, but five-year data was not statistically significant.

The company recently presented data June 3 at ASCO 2017 summarizing positive results of its Phase 2 trial in HER2-positive metastatic breast cancer that has metastasized to the brain. Nearly half of the patients in a neratinib plus chemotherapy cohort achieved a central nervous system (CNS) objective response with overall survival data remaining immature at 13.5 months (and counting). CNS progressions remain a huge comorbidity factor in patients with brain metastases. With the ability to cross the blood-brain barrier, and with diarrhea being the number one adverse event, PBYI is well-positioned to advance in this space with neratinib. Studies examining antidiarrheal prophylaxis (Loperamide) to reduce diarrhea severity during neratinib treatment have proven effective. Phase 3 data showed grade 3 diarrhea decreased from ~40% to ~31% with loperamide, to ~23% with loperamide and budesonide, and to 11.5% with loperamide and colestipol. Safety studies examining children and young adults with cancer are also ongoing.

Multiple studies are generating impressive cancer therapy data for neratinib, including clinical data presented at AACR on neratinib in the treatment of patients who have solid tumors with activating HER2 or HER3 mutations. Additional data was also presented on the combination of T-DM1 and neratinib in patients with HER2 positive metastatic breast cancer (MBC) that has previously been treated with pertuzumab and trastuzumab. The company has done extensive analysis of breast cancer NSABP FB-7 biomarker during neratinib treatment with a variety of immuno and chemotherapy regimens to qualify its objective tumor response. Mechanistically, phosphoHER2 levels and truncated HER2 mutants (p95HER2) demonstrated statistically significant higher levels in patients who achieved a pCR with neratinib than those treated with trastuzumab or trastuzumab plus neratinib who did not. Moreover, dual pathway suppression (HR/ER+ and EGFR/HER2+) has been seen only in neratinib and not in Herceptin and Tykerb (Novartis (NYSE:NVS)).

The company has listed other potential tissue types to expand its label for neratinib, including non-small cell lung cancer, colorectal cancer, and solid tumors (any HER2-associated tumors). Roche (OTCQX:RHHBY) annual sales for Herceptin (trastuzumab) approach $5 billion. In contrast, Tykerb has not fared as well due to its unfavorable toxicity profile, with sales in the hundreds of millions. The HER2 positive breast cancer market is estimated to be about $13 billion by 2023. Given this massive market and plenty of room to expand label into other high dollar indications, Puma may still have quite a bit of upside and is generally de-risked. It certainly becomes very attractive on any stock price pullbacks.

Puma reported at end of 1Q 2017 cash and cash equivalents of $105.1 million and marketable securities of $88.9 million, with a 1Q net loss of $72 million. Cash runway is expected to last through mid-2018, with a burn rate of approximately $35 million per quarter. If the company is forced to raise funds, it should be able to do so at a good market value, given the advanced stage of its drug development. Strong Bio recommends a watch list spot for the stock and manageable delays or setbacks as a potential buying opportunity. Moreover, it may be a takeover candidate and could undergo some downward volatility in the standard process of stop-loss triggering. Such swoons will probably not last long as market support should be strong. With market cap of $3 billion and potential market quite a bit larger, there is plenty of room for value position here if sales meet expectations.

Risks for the company to investors are primarily centered around its one-trick pony pipeline. But when the trick is good enough, it's going to bring bank. Its advantage in efficacy will certainly gain a reasonable stake in the market for those that can tolerate the adverse events. In fact, the adverse event of diarrhea is somewhat severe, but luckily, most of that risk was mediated with appropriate prophylaxis regimen. It perhaps would have contraindications for those with extreme inflammatory bowel or related disorders. FDA-related large scale manufacturing risks and regulatory hurdles could prove to add delays and pitfalls to Puma's terrain, and since this is the only revenue-maker in its pipeline, a lot hinges on its expeditious advancement. However, given the aggressive stance at FDA to get life-saving therapies available to patients, most regulatory risks are ameliorated. Partnership decisions will be important inflection points moving forward.

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article discusses one or more securities that do not trade on a major U.S. exchange. Please be aware of the risks associated with these stocks.

The rest is here:
Puma Stalks Up - Puma Biotechnology, Inc. (NYSE:PBYI) | Seeking ... - Seeking Alpha

Biotechnology crops dominate Nebraska crop fields | Agriculture … – Grand Island Independent

Biotechnology varieties of corn and soybeans make up 95 percent of the 15.5 million acres planted this spring by Nebraska farmers, according to a report from the USDAs National Agricultural Statistics Service on Friday.

According to the report, Nebraska corn growers planted 9.8 million acres, down 1 percent from last year. Biotechnology varieties were used on 96 percent of the area planted, up 1 percentage point from a year ago. Growers expect to harvest 9.5 million acres for grain, which is down 1 percent from last year.

Statewide, soybean planted area is estimated at 5.7 million acres, up 10 percent from last years total and a record high. Of the acres planted, 94 percent were planted with genetically modified, herbicide resistant seed, down 2 percentage points from a year ago. Acres expected to be harvested are 5.65 million, up 10 percent from a year earlier.

Last year, Nebraska ranked sixth in the nation in harvested acres of principal crops at 19,223,000 acres.

Nationwide, the USDA reported that corn planted area for all purposes in 2017 is estimated at 90.9 million acres, down 3 percent from last year. Compared with last year, planted acres are down or unchanged in 38 of the 48 estimating states. Area harvested for grain, at 83.5 million acres, is down 4 percent from last year.

Soybean planted area for 2017, nationwide, is estimated at a record high 89.5 million acres, up 7 percent from last year. Compared with last year, planted acreage intentions are up or unchanged in 24 of the 31 estimating states.

The USDA reported that winter wheat seeded in the fall of 2016 totaled 1.11 million acres, down 19 percent from last year and a record low. Harvested acreage is forecast at 1 million acres, down 24 percent from a year ago.

Along with declining wheat acres, Nebraska wheat farmers are also having to deal with a wheat virus outbreak that has reached epidemic levels and has been damaging fields and yields in the southern Nebraska Panhandle, according to the Associated Press. The Nebraska Wheat Association earlier this month reported that as many as 85 percent of southern Panhandle fields have been affected by the virus.

Nationwide, all wheat planted area for 2017 is estimated at 45.7 million acres, down 9 percent from 2016. This represents the lowest all wheat planted area on record since records began in 1919. The 2017 winter wheat planted area, at 32.8 million acres, is down 9 percent from last year. Of this total, about 23.8 million acres are hard red winter.

For other Nebraska crops, the USDA reported that:

Alfalfa hay acreage to be cut for dry hay is at 770 thousand acres, up 3 percent from 2016. Other hay acreage to be cut for dry hay is 1.70 million acres, unchanged from last year.

Sorghum acreage planted and to be planted, at 140 thousand acres, is down 30 percent from a year ago. The area to be harvested for grain, at 110 thousand acres, is down 37 percent from last year.

Oats planted area is estimated at 115 thousand acres, down 15 percent from the previous year. Area to be harvested for grain, at 25 thousand acres, is unchanged from a year ago.

Dry edible bean planted acreage is estimated at 150 thousand acres, up 9 percent from last year. Harvested acres are estimated at 139 thousand acres, up 14 percent from the previous year.

Proso millet plantings of 130 thousand acres are up 37 percent from a year ago.

Sugarbeet planted acres, at 49.7 thousand, are up 4 percent from last year.

Oil sunflower acres planted are estimated at 55 thousand, up 90 percent from last year. Non-oil sunflower planted acreage is estimated at 6 thousand acres, down 52 percent from a year ago and a record low.

Dry edible pea estimated planted acres are 45 thousand acres, down 18 percent from last year. Harvested acres are estimated at 42 thousand, down 19 percent from the previous year.

Visit link:
Biotechnology crops dominate Nebraska crop fields | Agriculture ... - Grand Island Independent

Where Does DERM Stock Rank in the Biotechnology Industry? – InvestorsObserver

Dermira Inc (DERM) is near the top in its industry group according to InvestorsObserver. DERM gets an overall rating of 55. That means it scores higher than 55 percent of stocks. Dermira Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 96 out of 148 industries.

Click Here to get the full Stock Score Report on Dermira Inc (DERM) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Dermira Inc (DERM) stock is lower by -1.78% while the S&P 500 has risen 0.05% as of 10:05 AM on Thursday, Nov 14. DERM is lower by -$0.14 from the previous closing price of $8.09 on volume of 24,562 shares. Over the past year the S&P 500 is up 14.58% while DERM is lower by -18.88%. DERM lost -$4.58 per share the over the last 12 months.

To see InvestorsObservers Sentiment Score for Dermira Inc click here.

Read more:
Where Does DERM Stock Rank in the Biotechnology Industry? - InvestorsObserver

Where Does KRYS Stock Rank in the Biotechnology Industry? – InvestorsObserver

The 64 rating InvestorsObserver gives to Krystal Biotech Inc (KRYS) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 89 percent of stocks in the Biotechnology industry, KRYSs 64 overall rating means the stock scores better than 64 percent of all stocks.

Click Here to get the full Stock Score Report on Krystal Biotech Inc (KRYS) Stock.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 64 means the stock is more attractive than 64 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Krystal Biotech Inc (KRYS) stock has fallen -1.62% while the S&P 500 is higher by 0.05% as of 9:56 AM on Thursday, Nov 14. KRYS is lower by -$0.83 from the previous closing price of $51.34 on volume of 1,982 shares. Over the past year the S&P 500 is higher by 14.58% while KRYS is higher by 132.66%. KRYS lost -$1.17 per share the over the last 12 months.

To see InvestorsObservers Sentiment Score for Krystal Biotech Inc click here.

View post:
Where Does KRYS Stock Rank in the Biotechnology Industry? - InvestorsObserver

Liquid Biopsy & Other Non-Invasive Cancer Diagnostics Market, 2030 Outlook – Advances in Biotechnology have Enabled the Establishment of Several…

Dublin, Dec. 19, 2019 (GLOBE NEWSWIRE) -- The "Liquid Biopsy and Other Non-Invasive Cancer Diagnostics Market (3rd Edition), 2019-2030: Focus on Circulating Tumor Markers such as CTCs, ctDNA, cfDNA, Exosomes and Other Biomarkers" report has been added to ResearchAndMarkets.com's offering.

This report provides an extensive study on liquid biopsy kits / assays that are either commercialized or are under development for diagnosis and / or monitoring of different types of cancer. In addition, it features an elaborate discussion on the likely future opportunity associated with such tests, over the next 10 years.

One of the key objectives of the report was to estimate the existing market size and potential future growth opportunities for non-invasive cancer diagnostics. Based on various parameters, such as number of available / under development products and estimated annual adoption rates, we have provided an informed estimate on the likely evolution of the market over the period 2019-2030. The report also features the likely distribution of the current and forecasted opportunity across:

[A] type of tumor marker (ctDNA, cfDNA, CTCs, exosomes, and others)[B] key applications (early diagnosis, patient monitoring and recurrence monitoring)[C] target disease indications (breast cancer, lung cancer, colorectal cancer, prostate cancer, bladder cancer, melanoma, gastric cancer, pancreatic cancer, ovarian cancer, and others)[D] end users (hospitals, research institutes and others)[E] key geographical regions (the US, the UK, Germany, Italy, Spain, France, Japan, Australia, China, India, and rest of the world)

In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

Advances in the field of biotechnology have enabled the establishment of several minimally invasive / non-invasive approaches for disease diagnosis

Amongst other promising diagnostic tools, liquid biopsy has emerged as a versatile and promising non-invasive cancer diagnostic tool. This procedure is based on the analysis of biofluids (such as blood, urine and / or plasma) in order to detect rare forms of biomarkers / tumor markers, such as circulating tumor cells (CTCs), circulating tumor DNA / RNA (ctNAs), circulating free DNA (cfDNA) and exosomes. Moreover, liquid biopsies have been demonstrated to be capable of assessing the stage of tumor at the time of sample extraction. Additionally, owing to the non-invasive nature of the test, it can be actively used to monitor / track changes in tumors, both before and during the course of treatment.

Other than liquid biopsy, the cancer diagnostics market has witnessed the emergence of several other non-invasive diagnostic technologies, which are based on analytes that are either superficially located (such as skin lesions) and / or are expelled from the body (such as bronchial fluids and exhaled breath). Most of the non-invasive diagnostic techniques mentioned above are backed by clinical data, validating their relevance and applicability across several types of solid tumors (such as breast cancer, lung cancer, ovarian cancer and pancreatic cancer) and hematological malignancies (such as leukemia and lymphoma). In future, non-invasive cancer diagnosis methods, particularly liquid biopsies, are anticipated to replace the existing invasive diagnostic techniques.

Amongst other elements, the report includes:

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/bcwnwi

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See the rest here:
Liquid Biopsy & Other Non-Invasive Cancer Diagnostics Market, 2030 Outlook - Advances in Biotechnology have Enabled the Establishment of Several...

Where Does JNCE Stock Rank in the Biotechnology Industry? – InvestorsObserver

The 74 rating InvestorsObserver gives to Jounce Therapeutics Inc (JNCE) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 96 percent of stocks in the Biotechnology industry, JNCEs 74 overall rating means the stock scores better than 74 percent of all stocks.

Click Here to get the full Stock Score Report on Jounce Therapeutics Inc (JNCE) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Jounce Therapeutics Inc (JNCE) stock is trading at $5.81 as of 10:05 AM on Thursday, Nov 14, a rise of $0.22, or 3.86% from the previous closing price of $5.59. The stock has traded between $5.62 and $6.19 so far today. Volume today is 195,167 compared to average volume of 163,071.

To see InvestorsObservers Sentiment Score for Jounce Therapeutics Inc click here.

Read the rest here:
Where Does JNCE Stock Rank in the Biotechnology Industry? - InvestorsObserver

Where Does FTSV Stock Rank in the Biotechnology Industry? – InvestorsObserver

The 59 rating InvestorsObserver gives to Forty Seven Inc (FTSV) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 81 percent of stocks in the Biotechnology industry, FTSVs 59 overall rating means the stock scores better than 59 percent of all stocks.

Click Here to get the full Stock Score Report on Forty Seven Inc (FTSV) Stock.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Forty Seven Inc (FTSV) stock is trading at $10.31 as of 10:05 AM on Thursday, Nov 14, a rise of $0.12, or 1.18% from the previous closing price of $10.19. The stock has traded between $10.28 and $10.57 so far today. Volume today is below average. So far 51,681 shares have traded compared to average volume of 211,996 shares.

To see InvestorsObservers Sentiment Score for Forty Seven Inc click here.

Follow this link:
Where Does FTSV Stock Rank in the Biotechnology Industry? - InvestorsObserver

If You Had Bought Puma Biotechnology (NASDAQ:PBYI) Stock Five Years Ago, Youd Be Sitting On A 97% Loss, Today – Simply Wall St

Long term investing works well, but it doesnt always work for each individual stock. We really hate to see fellow investors lose their hard-earned money. For example, we sympathize with anyone who was caught holding Puma Biotechnology, Inc. (NASDAQ:PBYI) during the five years that saw its share price drop a whopping 97%. And we doubt long term believers are the only worried holders, since the stock price has declined 83% over the last twelve months. On top of that, the share price has dropped a further 36% in a month.

We really hope anyone holding through that price crash has a diversified portfolio. Even when you lose money, you dont have to lose the lesson.

Check out our latest analysis for Puma Biotechnology

Given that Puma Biotechnology didnt make a profit in the last twelve months, well focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The companys revenue and earnings (over time) are depicted in the image below.

If you are thinking of buying or selling Puma Biotechnology stock, you should check out this FREE detailed report on its balance sheet.

While the broader market gained around 10% in the last year, Puma Biotechnology shareholders lost 83%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Regrettably, last years performance caps off a bad run, with the shareholders facing a total loss of 51% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. If you would like to research Puma Biotechnology in more detail then you might want to take a look at whether insiders have been buying or selling shares in the company.

We will like Puma Biotechnology better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Read more:
If You Had Bought Puma Biotechnology (NASDAQ:PBYI) Stock Five Years Ago, Youd Be Sitting On A 97% Loss, Today - Simply Wall St